Santhera Pharmaceuticals has signed a five-year exclusive agreement with Ikris Pharma Network to distribute Agamree (vamorolone) for the treatment of Duchenne muscular dystrophy in India, targeting patients aged four and older. Sales are expected to begin in Q4 2025 via named-patient supply, with Santhera receiving a percentage of net sales. The deal follows recent distribution arrangements in Turkey and several Gulf Cooperation Council countries, marking another step in Santhera’s asset-light global rollout for its dissociative steroid alternative to standard corticosteroids.
The move underscores a strategic push to seed access in high-need, price-sensitive markets ahead of full registrations. Rather than pursuing a traditional launch, Santhera is leveraging named-patient channels to test demand, establish clinician familiarity, and build real-world evidence in a market where out-of-pocket payment dominates and rare disease funding remains fragmented. The core strategic question is whether this model can establish a durable bridge to national approval and broader reimbursement in India, or whether it will remain a niche access route confined to self-pay and philanthropic support.
For patients and clinicians, the clinical value proposition is clear: an anti-inflammatory agent designed to maintain efficacy while potentially mitigating growth and bone-related toxicities associated with long-term corticosteroid use. In the pivotal program, Agamree demonstrated improved time-to-stand velocity compared to placebo at 24 weeks, with a safety profile characterized by mostly mild to moderate adverse events. For Indian HCPs, the near-term priority will be education on patient selection, dosing, and monitoring, alongside pharmacovigilance adapted to decentralized access. For payers and hospital administrators, the challenge will be reconciling premium therapy with constrained budgets and variable access pathways, particularly as patient advocacy groups and state programs influence funding decisions.
Commercially, Santhera is building a hybrid footprint, out-licensing in North America and China while utilizing specialized distribution partners in emerging markets to generate early revenues and data with minimal operational overhead. In India, the competitive reference point remains low-cost prednisone and deflazacort. Adoption will hinge on clear differentiation that translates into quality-of-life and function outcomes meaningful to families and clinicians, supported by health-economic models that capture avoided complications and caregiver burden. Expect patient support programs, diagnostic partnerships, and center-of-excellence strategies to be central to uptake. With gene therapies still distant from routine availability in India, a better-tolerated steroid alternative could position itself as the pragmatic standard over the medium term.
This agreement also reflects a broader trend in the commercialization of rare diseases: the rise of named-patient and early-access pathways as both access and evidence-generation strategies. Companies are increasingly using these routes to establish clinical narratives, secure KOL advocacy, and inform pricing corridors before committing to complete regulatory filings. Success, however, depends on robust real-world data capture, transparent safety reporting, and thoughtful engagement with national rare disease policies to mitigate reputational risk associated with affordability.
The next twelve to eighteen months will reveal whether Santhera and Ikris can convert early access into scalable demand. Watch for initial shipment volumes in late 2025, the establishment of real-world registries and center-based protocols, and signals of movement toward formal Indian registration and structured reimbursement. The sharper question for the industry: Can named-patient distribution in large emerging markets evolve from a stopgap access solution to a repeatable market-building engine for rare disease therapeutics without sacrificing affordability or evidence standards?
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
